新型抗凝血药物的研究进展

Research Progress of Novel Anticoagulants

当前临床上主要的抗凝血药物如肝素、华法林及重组水蛭素等存在出血,需要实验室监测,药物半衰期短等不足。以pegmusirudin、HD1-22、flovagatran、otamixaban、RB-006、EP217609等为代表的新型抗凝血药物克服了现有抗凝剂的诸多不足,为抗凝和溶栓治疗提供了更多选择。本文就相关研究及进展进行综述。

The current anticoagulants available to clinicians such as heparin,warfarin and recombinant hirudins（i.e.bivalirudin,desirudin,lepirudin） have some drawbacks including heparin-induced bleeding,need of laboratory monitoring of warfarin and short half-life of hirudin in vivo.Novel parenteral anticoagulants in development representative by pegmusirudin,HD1-22,flovagatran,otamixaban,RB-006,EP217609 overcome the shortcoming of anticoagulants available now.They provide more alternatives to anticoag-ulant therapy and thrombolytic therapy.The review addresses the advance of novel anticoagulants in development.